Evaluation of MN-166 (Ibudilast) for 12 Months Followed by an Open-label Extension for 6 Months in Patients With ALS
Trial details
- Registry ID
- NCT04057898
- Phase
- Phase 2, Phase 3
Drug identity checked against registry records
Also recorded as ibudilast
| Trial | Sponsor | Phase | Status | Primary completion |
|---|---|---|---|---|
| Evaluation of MN-166 (Ibudilast) for 12 Months Followed by an Open-label Extension for 6 Months in Patients With ALSNCT04057898 | MediciNova | Phase 2, Phase 3 | Active not recruiting | 2027-04Estimated |
| No regulatory events match this view.This does not mean no FDA events have occurred. |